GNPX - Genprex, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0700
-0.1100 (-9.32%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.1800
Open1.1700
Bid0.5000 x 1100
Ask1.3000 x 1000
Day's Range1.0700 - 1.1700
52 Week Range0.9500 - 7.8800
Volume63,258
Avg. Volume38,207
Market Cap16.693M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.9430
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.25
Trade prices are not sourced from all markets
  • GuruFocus.com14 days ago

    5 Immunotherapy Stocks to Keep a Close Eye On

    Immunotherapy is changing the face of cancer treatment as we know it, creating compelling investment opportunities

  • Business Wire22 days ago

    Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination with Immunotherapy for Non-Small Cell Lung Cancer

    Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company, today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC). In July 2018, the company entered a Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to fund a research study entitled, “A Novel Therapeutic Approach for the Treatment of Cancer Using a Combination of the Multifactorial Tumor Suppressor Gene TUSC2 and Immunotherapy.” The TUSC2 gene is the active agent in Genprex’s Oncoprex immunogene therapy.

  • GlobeNewswire2 months ago

    Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Gene Therapy as Potential Cancer Treatment

    Preliminary results show that Oncoprex has the potential to become an effective add-on therapy for the treatment of deadly non-small cell lung cancer. Genprex Inc. (GNPX) plans to expand the current erlotinib-Oncoprex trial to multiple research centers and conduct more new trials. If Phase II results are as positive as preliminary indications, it could spark a rally in the shares and possibly even lure a large biotechnology or pharma company to sign a high-value partnership with Genprex.

  • GlobeNewswire2 months ago

    Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Hunt for Gene Therapy Breakthroughs  

    NEW YORK, May 30, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.

  • Business Wire2 months ago

    Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum

    Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019. Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. Genprex will be among the 30+ presentations by listed and private biotechnology companies at the event.

  • GlobeNewswire2 months ago

    Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Promising New Gene Therapies

    Gene therapies, the promising treatments pursued by companies such as Genprex Inc. (GNPX), are based on turning [the] problem [of cell mutation] on its head. Once in place, successful gene therapies replace damaged or missing code and help the body cure itself. Creating these treatments is challenging work, and the companies that excel are innovators with the ability to try new approaches.

  • GlobeNewswire2 months ago

    Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Gene Therapies for Cancer Treatment

    NEW YORK, May 08, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.

  • Business Wire2 months ago

    Genprex Retains Addison Whitney for Drug Nomenclature Branding

    Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of leading pharmaceutical branding agency, Addison Whitney. Addison Whitney, a Syneos Health company, will draw from its 28-year history to oversee the proprietary and non-proprietary drug naming process for Genprex’s lead drug candidate, currently known as Oncoprex™ immunogene therapy, for non-small cell lung cancer. Oncoprex immunogene therapy has shown promise in targeting and treating non-small cell lung cancer (NCSLC) through its proprietary technology platform, which transports cancer-fighting genes to cancerous cells by encapsulating the genes into nanoscale hollow spheres, called nanovesicles, which are then administered intravenously.

  • Newsfile3 months ago

    Genprex Featured in NetworkNewsAudio Broadcast on Potential Gene Therapy Treatment for Cancer

    New York, New York--(Newsfile Corp. - April 12, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio broadcast titled, "Potential Blockbuster Gene Therapy Programs to Watch in 2019."To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/j1WMsTo read the full editorial, visit: http://nnw.fm/YC9iqGenprex already has over 30 issued patents for its platform technologies. The company's promising pipeline currently includes a phase I/II clinical trial underway to evaluate intravenous Oncoprex immunogene therapy in ...

  • GlobeNewswire3 months ago

    Genprex (GNPX) Featured in NetworkNewsAudio Broadcast Discussing Gene Therapy Programs on the Cusp of Curing the Incurable

    The company’s promising pipeline currently includes a phase I/II clinical trial underway to evaluate intravenous Oncoprex immunogene therapy in combination with another cancer drug, Tarceva, and pre-clinical research of the combination of Oncoprex immunogene therapy with immunotherapies. Gene therapy programs may be on the cusp of curing the incurable, and the companies that deliver these medical miracles are in an ideal position to reap a bonanza of recognition and rewards. Given the promise of Genprex’s pipeline of cancer killers with global blockbuster potential, the company certainly appears to be one to watch.

  • Newsfile3 months ago

    Genprex (GNPX) Featured in NetworkNewsWire Publication about Revolutionary Gene Therapies

    New York, New York--(Newsfile Corp. - April 11, 2019) - Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.To view the full publication, titled "Potential Blockbuster Gene Therapy Programs to Watch in 2019," visit: http://nnw.fm/YC9iqPerhaps no other disease strikes as much dread and fear as cancer. Many successful treatments are available today that didn't exist just ...

  • GlobeNewswire3 months ago

    Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Cancer and Gene Therapy Treatment

    NEW YORK, April 11, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.

  • Business Wire3 months ago

    Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting

    TUSC2 Immunogene Therapy Overcomes Resistance to Checkpoint Blockade

  • Business Wire4 months ago

    Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018

    Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission. “Over the past year, we made great progress in advancing the development of our gene therapy platform, including Oncoprex™ immunogene therapy for non-small cell lung cancer,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “I’m pleased with our progress and am excited to continue development of our gene therapies for cancer into 2019 and beyond.

  • Newsfile4 months ago

    Genprex Featured in NetworkNewsAudio Publication on Unprecedented Targeting in Cancer Treatment

    New York, New York--(Newsfile Corp. - March 29, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio publication titled, "Advanced Medical Technologies Provides Unprecedented Targeting in Cancer Therapy."To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/XRt4dTo read the full editorial, visit: http://nnw.fm/tB7LiA multiplicity of potential breakthrough treatments to fight cancer are in varying stages of clinical development, and many are focused on the promise of advanced gene therapies. Genprex Inc. (NASDAQ: ...

  • GlobeNewswire4 months ago

    Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Advanced Medical Cancer Therapy

    A multiplicity of potential breakthrough treatments to fight cancer are in varying stages of clinical development, and many are focused on the promise of advanced gene therapies. Genprex Inc. (GNPX) (GNPX Profile) is working to bring its potentially life-changing immunogene therapy, Oncoprex, to market. Genprex already has 30 issued patents for its platform technologies and gene therapies.

  • GlobeNewswire4 months ago

    Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Innovative Cancer Treatments

    NEW YORK, March 28, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.

  • Newsfile4 months ago

    Genprex Featured in NetworkNewsWire Publication on Innovations in Cancer Therapy

    New York, New York--(Newsfile Corp. - March 28, 2019) - Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.To view the full publication, titled "Advanced Medical Technologies Provides Unprecedented Targeting in Cancer Therapy," visit: http://nnw.fm/l3DkVGenprex is on the cusp of potentially delivering life-changing therapeutics for cancer patients by utilizing the company's novel proprietary technology platform. ...

  • GlobeNewswire4 months ago

    Genprex Inc. Discusses Plans to Expand Clinical Trials in Fight Against Cancer in Exclusive Audio Interview with NetworkNewsWire

    NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with Genprex Inc., a clinical stage gene therapy company developing a new approach to treating cancer. NNW’s Stuart Smith introduces Genprex CEO and Chairman Rodney Varner, JD, for a compelling discussion on the company’s initial product candidate, Oncoprex(TM), an immunogene therapy for non-small cell lung cancer (NSCLC). The American Cancer Society reports that NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancer.

  • Newsfile4 months ago

    NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.'s Transformative Work in Gene Therapy

    New York, New York--(Newsfile Corp. - March 15, 2019) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Making Profits, Saving Lives with Gene Therapy," featuring Genprex Inc. (NASD: GNPX).To hear the NetworkNewsAudio version, visit: http://nnw.fm/bw1cXTo read the full editorial, visit: http://nnw.fm/Y0ZqHThis evidence of the faith of the markets has helped boost stock values for a range of gene therapy companies, with some seeing triple digit growth. But these companies don't need to be the ...

  • GlobeNewswire4 months ago

    NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.’s Innovative Approach to Gene Therapy

    NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Making Profits, Saving Lives with Gene Therapy,” featuring Genprex Inc. (GNPX). Delivery systems for the genes are as important as the genes themselves. Carriers called vectors deliver the genetic material into the cells.

  • GlobeNewswire4 months ago

    NetworkNewsWire Announces Publication on Gene Therapy’s Promise for Improving Patient Treatments and Market Profitability

    NEW YORK, March 14, 2019 -- via NetworkWire — NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial.

  • Business Wire4 months ago

    Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City

    Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019.

  • GuruFocus.com4 months ago

    5 Biotech Stocks to Keep an Eye on in 2019

    The biotech sector is an interesting one to follow. Warning! GuruFocus has detected 2 Warning Sign with CELG. There has been quite a bit of chatter recently surrounding the potential acquisition of the company by Bristol-Myers Squibb (BMY).

  • Business Wire5 months ago

    Genprex Strengthens Senior Team and Continues to Advance Operations

    Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform announced that it is continuing to grow its senior team with the hiring of Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing, effective immediately.